Compare Gilead Sciences, Inc. (GILD) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $149.4 (market cap $182.40B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.08 (market cap $27.10B). The key difference: Gilead Sciences, Inc. is far larger — about 6.7× Vanguard S&P 500 Growth Index Fund ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| GILD | VOOG | |
|---|---|---|
Market Cap | $182.40B | $27.10B |
Volume | 4,469,821 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $87.81 |
52-Week Low | $116.74 | $65.32 |
Typical Hold Time | 111 Days | 54 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
VOOG trades at $87.69, down slightly by 0.14% on the day, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including an overbought RSI. The ETF, tracking the S&P 500 Growth Index, has delivered strong long-term returns, with recent news highlighting institutional buying and outperformance versus peers. Key support sits at $87, resistance at $88.
Outlook remains positive for long-term growth investors given VOOG's low expense ratio and historical outperformance, though near-term risks include tech sector concentration and market volatility. The ETF's focus on large-cap growth stocks positions it well for sustained appreciation, but investors should be cautious of valuation extremes in growth segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
